Lv1
20 积分 2025-01-09 加入
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
3个月前
已完结
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
3个月前
已完结
A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population
3个月前
已完结
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
3个月前
已完结
Targeting MET in cancer: rationale and progress
3个月前
已完结
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
3个月前
已关闭
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
3个月前
已完结
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
3个月前
已完结
Non-Small Cell Lung Cancer
3个月前
已关闭
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
3个月前
已完结
皖公网安备34019202002308
